Literature DB >> 11080684

Transcriptional regulation of inflammatory secreted phospholipases A(2).

M Andreani1, J L Olivier, F Berenbaum, M Raymondjean, G Béréziat.   

Abstract

Secreted phospholipases A(2) is a family of small molecular weight and calcium-dependent enzymes of which the members list is presently growing. Among these enzymes, the synovial type IIA and the type V phospholipases A(2) are involved in inflammation. Although their actual mechanism is still a subject of debate, new therapeutic strategies can result from the knowledge of the regulations of their gene expression. The human genes of the type IIA and type V phospholipases A(2) are located on the chromosome 1 at close positions and transcribed in reverse orientations. These genes can therefore be regulated by common elements but only the regulation of the type IIA phospholipase A(2) gene expression has been extensively studied. Pro-inflammatory cytokines upregulate while the growth factors downregulate the type IIA phospholipase A(2) gene expression. Interleukin-6 and interleukin-1beta exert their effects at least partially at the transcriptional level. The transcriptional regulation of the type IIA phospholipase A(2) gene is cell- and species-specific. The activity of the human promoter is controlled by the CAAT-enhancer binding protein (C/EBP) factors while that of the rat promoter is regulated by nuclear factor kappaB (NF-kappaB) and C/EBPs. Furthermore, the human promoter is constitutively repressed in hepatocytes by single strand DNA binding proteins whose effects are relieved by C/EBP factors while the glucocorticoid receptor interacts with C/EBPs in chondrocytes to achieve full basal and interleukin-1beta-stimulated transcription activity. Other factors like CTF/NF1 and Sp1 might be involved in the regulation of both the rat and human promoter. Peroxisome proliferator-activated receptors could contribute to the stimulation of the rat promoter by NF-kappaB in vascular smooth muscle cells. The study of the coactivators and coinhibitors associated to these transcription factors will give a better understanding of the diversity and complexity of the transcriptional regulations of the type IIA phospholipase A(2) gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080684     DOI: 10.1016/s1388-1981(00)00117-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  A proximal tissue-specific module and a distal negative regulatory module control apolipoprotein(a) gene transcription.

Authors:  Sarita Negi; Saurabh K Singh; Nirupma Pati; Vikas Handa; Ruchi Chauhan; Uttam Pati
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

2.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

3.  Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes.

Authors:  Michael D Jensen; Wenwen Sheng; Agnes Simonyi; Gary S Johnson; Albert Y Sun; Grace Y Sun
Journal:  Neurochem Int       Date:  2009-04-16       Impact factor: 3.921

4.  Interferon gamma-induced gene expression of the novel secretory phospholipase A2 type IID in human monocyte-derived macrophages is inhibited by lipopolysaccharide.

Authors:  John Lindbom; Anders G Ljungman; Christer Tagesson
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

5.  Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis.

Authors:  Sang-Ho Choi; Robert Langenbach; Francesca Bosetti
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

6.  Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Heike Kostka; Graeme Eisenhofer; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 7.  Phospholipases A2 and inflammatory responses in the central nervous system.

Authors:  Grace Y Sun; Phullara B Shelat; Michael B Jensen; Yan He; Albert Y Sun; Agnes Simonyi
Journal:  Neuromolecular Med       Date:  2009-10-24       Impact factor: 3.843

8.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

9.  Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.

Authors:  Daniele De Luca; Silvia Baroni; Giovanni Vento; Marco Piastra; Domenico Pietrini; Federica Romitelli; Ettore Capoluongo; Costantino Romagnoli; Giorgio Conti; Enrico Zecca
Journal:  Intensive Care Med       Date:  2008-07-22       Impact factor: 17.440

10.  C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia.

Authors:  Yan Xu; Chika Saegusa; Angelica Schehr; Shawn Grant; Jeffrey A Whitsett; Machiko Ikegami
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-22       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.